ESMO AI & Digital Oncology Congress 2026

Date: November 16, 2026 - November 18, 2026
Type: In-person
Location: Europe
Areas of Interest: BioPharma, Oncology

We are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our MultimWe are delighted to participate in the ESMO AI & Digital Oncology Congress 2026, where you can meet with our Multimodal and BioPharma teams for three exciting days of innovation, networking, and insights into AI-powered solutions and breakthroughs to transform precision oncology.

Join us at booth #08 to:

Explore how the SOPHiA DDM™ Platform transforms complex multimodal oncology data into actionable insights with AI-powered analytics
Empower more confident decision-making with SOPHiA DDM™ Digital Twins by comparing similar patient profiles and simulating potential response outcomes
Harness the global collective intelligence of our network to uncover valuable insights and advance precision oncology through data-driven innovation

We look forward to seeing you at our presentation on Tuesday, November 17^th from 10.00 to 10.30, on the Exhibition Hall stage.

“Beyond Genomics: Shaping the Next Era of Precision Medicine”

Join Ryan Woodhouse, VP, Head of Regulatory Affairs, SOPHiA GENETICS, to explore how precision medicine has evolved from molecular diagnostics to AI-driven multimodal approaches, and learn about SOPHiA GENETICS’ pivotal role in this transformation. This insightful session will examine how multimodal intelligence, next-generation diagnostics, and Digital Twins are revolutionizing clinical decision-making, while also exploring the regulatory frameworks and responsible adoption strategies necessary as AI becomes increasingly central to precision healthcare.

Register Now

URL

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Company(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

Job Title/Industry(Required)

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services